The National Cancer Center said Wednesday it has signed a materials transfer agreement with Canada’s Applied Biological Material (ABM), to provide the latter with independently developed cancer cell line that concerns the protein CD44v8-10.
|Researcher Goh Sung-ho (left) and Choi Yong-doo from the National Cancer Center|
The transfer agreement will allow the Vancouver, Canada-based ABM to access research materials for the cancer cell line and supply it to researchers around the world, NCC said.
The cancer cell line in question, developed by the NCC’s research team led by researchers Goh Sung-ho and Choi Yong-doo, overexpresses the CD44v8-10 protein. Cancer cell lines are used in research to study how cancer cells divide and grow over time and are used to test cancer treatments.
“We expect the materials transfer agreement will be a big help in developing cancer-specific diagnostic and therapeutic agents,” the center said.
NCC added that it would analyze the potential of cancer-specific biomarkers in the future, and actively develop new bio-based materials linked to the treatment of patients.
The research results were published in the July 2017 edition of Scientific Reports, a sister publication of the international journal Nature.
<© Korea Biomedical Review, All rights reserved.>